Comparison of preservative-free versus preserved dexamethasone and diclofenac eye drops in patients after cataract surgery

3 1 1 1

What is this study about?

This study focuses on treating patients who have undergone cataract surgery. A cataract is a condition where the natural lens of the eye becomes cloudy, making it difficult to see clearly. The study compares two different types of eye drop treatments – one group contains preservatives while the other is preservative-free. The medications being tested are dexamethasone (Monofree Dexamethason and Maxidex) and diclofenac (Dicloabak and Voltaren Ophtha) eye drops.

The purpose of this research is to determine if preservative-free eye drops work better than preserved eye drops after cataract surgery. During the study, participants receive either preservative-free or preserved eye drops for their post-surgery treatment. The treatment continues for 4 weeks after the cataract surgery.

Both types of eye drops contain the same active medicines – dexamethasone, which reduces inflammation, and diclofenac, which helps manage pain and inflammation. The only difference between the two treatment groups is that one contains preservatives while the other does not. The study measures various aspects of eye health, including tear production, eye surface condition, and inflammation levels.

1 Initial eye examination after cataract surgery

Your eyes will be examined after the cataract surgery to establish a baseline for the study.

You will be assigned to one of two treatment groups: either preservative-free eye drops or preserved eye drops.

2 Eye drop treatment begins

You will receive two types of eye drops to use:

Dexamethasone 0.1% eye drops (either Monofree Dexamethason or Maxidex)

Diclofenac 0.1% eye drops (either Dicloabak or Voltaren Ophtha)

Both medications are for ocular use (application directly to the eye)

3 Regular eye examinations

Your eyes will be checked regularly for various factors including:

Tear quality and quantity

Eye surface condition

Eye redness

Cornea (front surface of the eye) health

Macular (central retina) thickness

4 Final assessment

At week 4 after surgery, a final detailed examination will be performed

The main measurement will focus on the level of inflammation inside your eye

Additional measurements will include tear analysis and eye surface condition

Who Can Join the Study?

  • You must be 60 years of age or older
  • You must have been diagnosed with age-related cataract (clouding of the natural lens in your eye that occurs with aging)
  • Both men and women can participate in the study
  • You must be able to undergo cataract surgery (a procedure to remove the cloudy lens and replace it with an artificial one)
  • You must be willing to use eye drops after surgery as prescribed in the study
  • You must be mentally capable of understanding and providing informed consent for participation
  • You must not be part of any vulnerable population groups

Who Cannot Join the Study?

  • Age below 18 years old
  • Known allergies to any components of eye drops used in the study
  • Current eye infections or active inflammation
  • Previous eye surgery within the last 6 months
  • Presence of other serious eye conditions besides cataract
  • Pregnancy or breastfeeding
  • Participation in another clinical trial within the last 30 days
  • Inability to follow study instructions or attend follow-up visits
  • Severe dry eye syndrome (a condition where eyes don’t produce enough tears)
  • Use of contact lenses
  • Uncontrolled glaucoma (increased pressure inside the eye)
  • History of complicated cataract surgery
  • Mental conditions that may affect the ability to provide informed consent
  • Severe systemic diseases that could interfere with the study

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Katholieke Universiteit te Leuven Leuven Belgium

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
03.10.2018

Trial locations

Dexamethasone is an anti-inflammatory steroid eye drop medication used to reduce inflammation and discomfort after cataract surgery. It helps to decrease swelling, redness, and irritation in the eye following the procedure.

Diclofenac is a non-steroidal anti-inflammatory eye drop medication that helps reduce pain and inflammation after cataract surgery. It works by blocking certain substances in the body that cause inflammation and discomfort.

Both medications are available in two forms in this trial: preservative-free formulations and formulations containing preservatives. Preservative-free eye drops are generally gentler on the eye’s surface and may be better tolerated by some patients, while preserved eye drops contain additional ingredients to keep the medication sterile for longer periods.

Investigated diseases:

Cataract – A condition where the natural lens of the eye becomes cloudy and opaque, leading to decreased vision quality. The lens gradually loses its transparency as proteins within it break down and clump together, causing light to scatter instead of focusing properly on the retina. This clouding typically develops slowly over time and can affect one or both eyes. Cataracts commonly cause blurred vision, increased glare sensitivity, and changes in color perception. The condition is most often associated with aging, though it can occur at any age.

Trial ID:
2024-517572-38-00
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of herbal medicine combination and bromazepam for anxiety and pain in patients having eye surgery with retrobulbar anesthesia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Austria
  • Comparing the effectiveness of nepafenac and dexamethasone sodium phosphate for treating eye inflammation after cataract surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Italy